Tarek Taha

Dr. Tarek Taha

Rambam Health Care Campus

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
TTTarek Taha
Tarek Taha
RKRasha Khoury
Rasha Khoury
RBRonen Brenner
Ronen Brenner
HNHaitam Nasrallah
Haitam Nasrallah
ISIrena Shofaniyeh
Irena Shofaniyeh
Abed AgbaryaAbed Agbarya
Abed Agbarya
Lung cancer is a worldwide prevalent malignancy. This disease has a low survival rate due to diagnosis at a late stage challenged by the involvement of metastatic sites. Non-small-cell lung cancer (NSCLC) is presented in 85% of cases. The last decade has experienced substantial advancements in scientific research, leading to a novel targeted therapeutic approach. The newly developed pharmaceutical agents are aimed towards specific mutations, detected in individual patients inflicted by lung cancer. These drugs have longer and improved response rates compared to traditional chemotherapy. Recent studies were able to identify rare mutations found in pulmonary tumors. Among the gene alterations detected were mesenchymal epithelial transition factor (MET), human epidermal growth factor 2 (HER2), B-type Raf kinase (BRAF), c-ROS proto-oncogene (ROS1), rearranged during transfection (RET) and neurotrophic tyrosine kinase (NTRK). Ongoing clinical trials are gaining insight onto possible first and second lines of medical treatment options intended to enable progression-free survival to lung cancer patients.

3 November 2020 in BioDrugs
Verified
Journal Article
Closed access
PDF file
TTTarek Taha
Tarek Taha
ARAri Reiss
Ari Reiss
AAAmnon Amit
Amnon Amit
RPRuth Perets
Ruth Perets